

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

SK-N-BE(2)

RRID:CVCL_0528

Type: Cell Line

Proper Citation

RRID:CVCL_0528

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0528

Proper Citation: RRID:CVCL_0528

Description: Cell line SK-N-BE(2) is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Neuroblastoma

Defining Citation: [PMID:29704](#), [PMID:62055](#), [PMID:2535691](#), [PMID:6582512](#), [PMID:7838528](#), [PMID:11507071](#), [PMID:11550280](#), [PMID:15720811](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:20215515](#), [PMID:20631050](#), [PMID:20655465](#), [PMID:22213050](#), [PMID:22460905](#), [PMID:24792489](#), [PMID:25877200](#), [PMID:25884760](#), [PMID:28350380](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Characteristics: Substrate-adherent type (S-type) (PubMed=15720811)., Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-N-BE(2)

Synonyms: SK-N-BE2, SK-N-BE-2, SKNBE(2), SKNBE-2, SKNBE2, SK-N-BE, SKNBE

Cross References: BTO:BTO_0002696, CLO:CLO_0009052, EFO:EFO_0022401, MCCL:MCC:0000505, CLDB:cl4332, CLDB:cl4333, Abcam:ab275476, ArrayExpress:E-MTAB-2770, ATCC:CRL-2271, BCRJ:0381, BioGRID_ORCS_Cell_line:375, BioSample:SAMN03472880, BioSample:SAMN03473451, BioSample:SAMN10988136,

cancer cell lines: CVCL_0528, CancerTools:161921, CCRID:3101HUMTCHu200, Cell_Model_Passport:SIDM00894, CLS:305058, Cosmic:1019928, Cosmic:2485941, DepMap:ACH-000312, DSMZ:ACC-632, DSMZCellDive:ACC-632, ECACC:95011815, GEO:GSM554389, GEO:GSM563358, GEO:GSM692869, GEO:GSM827352, GEO:GSM887593, GEO:GSM888676, GEO:GSM1366411, GEO:GSM1670450, GEO:GSM2371255, GEO:GSM2394375, IARC_TP53:30154, ICLC:HTL96015, KCB:KCB 2011099YJ, LiGeA:CCLE_929, LINCS_LDP:LCL-1980, MetaboLights:MTBLS104, PharmacDB:SKNBE_2_1405_2019, PRIDE:PXD002635, Progenetix:CVCL_0528, Wikidata:Q54954442

ID: CVCL_0528

Record Creation Time: 20220427T221547+0000

Record Last Update: 20260905T182406+0000

Ratings and Alerts

No rating or validation information has been found for SK-N-BE(2).

No alerts have been found for SK-N-BE(2).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 461 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Lapidus T, et al. (2026) Irinotecan Modulates Immune Checkpoints in Neuroblastoma. ImmunoTargets and therapy, 15, 598469.

Chaves GS, et al. (2026) Hypoxia Promotes an Adrenergic to Mesenchymal Transcriptional Program Transition in Neuroblastoma. Clinical and translational science, 19(3), e70508.

Zhou E, et al. (2026) NDUFS6 promotes neuroblastoma progression and represents a potential therapeutic target. Translational pediatrics, 15(5), 187.

Yu X, et al. (2026) Towards a unified molecular mechanism for ligand-dependent activation of NR4A-RXR heterodimers. eLife, 14.

Guyot C, et al. (2026) IL4i1 activity generates oncometabolites that rescue neuroblastoma cells from oxidative death. Cell reports, 45(6), 117441.

Calderoni M, et al. (2026) 45A ncRNA Expression Leads to Chromosomal Instability and Cytoskeletal Dynamics Impairment by Modulating GTSE1/p53/AurB Subcellular

Localization. International journal of molecular sciences, 27(11).

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. Cancers, 18(3).

Xu A, et al. (2026) Acyltransferase ZDHHC22 promotes N-Myc transcriptional activation to drive neuroblastoma progression and chemoresistance. Molecular cell, 86(10), 1945.

Frapolli R, et al. (2026) Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy. iScience, 29(1), 114449.

Lou E, et al. (2026) Super-enhancer-driven TCF4 orchestrates neuroblastoma metastasis by sphingolipid-dependent membrane remodeling and ITGB1-FAK activation. Neuro-oncology, 28(5), 1335.

Dong Y, et al. (2026) KSRP-dependent immunogenic cell death induced by pyridazinone derivative IMB5036 drives antitumor immunity in neuroblastoma. FEBS letters.

Pommerenke C, et al. (2026) Neuronal differentiation of neuroblastoma cell lines for neurological disease modeling. iScience, 29(7), 116469.

Wang X, et al. (2025) Spatial and Single-Cell Analyses Reveal Heterogeneity of DNAM-1 Receptor-Ligand Interactions That Instructs Intratumoral ??T-cell Activity. Cancer research, 85(2), 277.

Treis D, et al. (2025) Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. Cell death & disease, 16(1), 318.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. Cell reports. Medicine, 6(10), 102411.

Graham MK, et al. (2024) The TERT Promoter is Polycomb-Repressed in Neuroblastoma Cells with Long Telomeres. Cancer research communications, 4(6), 1533.

Abdelfattah NS, et al. (2024) T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics. Immunity, 57(12), 2945.

Kaufman ME, et al. (2024) Characterizing Relationships between T-cell Inflammation and Outcomes in Patients with High-Risk Neuroblastoma According to Mesenchymal and Adrenergic Signatures. Cancer research communications, 4(8), 2255.

Thombare K, et al. (2024) METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma. The EMBO journal, 43(24), 6310.

Zaghmi A, et al. (2024) High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance. Molecular oncology, 18(2), 317.